Genzyme, one of the world's leading biotechnology companies, receives EU quality mark for its single-treatment Synvisc-One.
Synvisc-One, the single treatment of Synvisc has been shown by the European Union to provide up to six months of proven pain relief from osteoarthritis of the knee.
It is now the only viscosupplementation product available in Europe that is labeled to provide this long-term duration of pain relief from a single injection.
Pain management
Cambridge, MA.-based Genzyme said it believes that Synvisc-One will simplify osteoarthritis pain management and provide added patient convenience, while reducing the overall cost of therapy associated with multiple injections and offering a treatment option that will expand the benefits of viscosupplementation to a broader number of patients.
“Delivering the benefits of Synvisc through one treatment rather than three will provide additional options for physicians and their patients to reduce the cost and burden of multiple injections,” said Ann Merrifield, president of Genzyme Biosurgery, the business unit of Genzyme Corp. that manufactures and markets Synvisc.
Eliminating risk
“Synvisc-One provides long-term pain relief for patients without the systemic safety risks associated with traditional OA therapies such as NSAIDs and COX2 inhibitors,” stated Xavier Chevalier M.D., Head of Rheumatology, Hôpital Henri Mondor, Créteil France.
“This is a unique opportunity for physicians to treat patients with a single injection viscosupplement that offers a very good risk-benefit profile.”
Genzyme will also pursue marketing approvals for Synvisc-One in wider geographies in Canada, Asia and Latin America based on the European CE mark approval.
December 19, 2007